Lv3
288 积分 2021-04-15 加入
Time-varying pattern of recurrence risk for Chinese breast cancer patients
18天前
已完结
Suboptimal health literacy in patients with lung cancer or head and neck cancer
1个月前
已完结
Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer
1个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
1个月前
已完结
Nanoformulation-based sequential combination cancer therapy
1个月前
已完结
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
1个月前
已完结
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis
2个月前
已关闭
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
2个月前
已完结
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
2个月前
已完结
皖公网安备34019202002308
